Spinal Muscular Atrophy

Spinal Muscular Atrophy (SMA) is an autosomal recessive, progressive neuromuscular disease characterized by the degeneration of lower motor neurons in the anterior horn of the spinal cord. This loss leads to muscle weakness, muscle atrophy, and respiratory insufficiency of varying severity.

SMA is caused by a homozygous deletion or mutation in the Survival Motor Neuron 1 (SMN1) gene on chromosome 5q

1. The severity of the disease is modulated by the copy number of a highly homologous centromeric duplicate gene, SMN2.

The lack of functional SMN1 protein impairs spliceosome assembly and RNA metabolism. This deficiency selectively triggers the degeneration of alpha motor neurons in the spinal cord, causing denervation muscle atrophy, progressive proximal-to-distal weakness, and eventual diaphragmatic breathing dependency.

• Incidence: Approximately 1 in 10,000 live births.
• Carrier Frequency: 1 in 40 to 1 in 60 globally.
• Demographics: Affects males and females equally, manifesting from infancy to adulthood.

• Consanguineous parental relationships.

• Vital Signs: Tachypnea, paradoxical breathing pattern.
• Inspection: Symmetric proximal muscle wasting, bell-shaped trunk, tongue fasciculations, polyminimyoclonus (fine hand tremors).
• Neurological: Hyporeflexia or areflexia, marked generalized flaccid hypotonia.

• A. Clinical Assessment: Motor milestone delay, hypotonia, areflexia.
• B. Laboratory Testing: Normal or mildly elevated serum creatine kinase.
• C. Imaging Studies: Spinal radiographs to monitor progressive neuromuscular scoliosis.
• D. Functional Tests: CHOP-INTEND (infants) or HFMSE (older children) scales.
• E. Biopsy Findings: Muscle biopsy shows diagnostic groups of panfascicular atrophic fibers interspersed with hypertrophied type 1 fibers.

• G. Differential Diagnosis: Congenital myopathies, ALS, Pompe disease, Guillain-Barré syndrome.

SMN1 / *SMN2

• Gene Copy Number Analysis

• Spinal Radiographs: Used to monitor and grade neuromuscular scoliosis. Typically shows progressive C-shaped thoracolumbar curvature.
• Chest X-ray: Evaluates baseline diaphragmatic elevation and rules out atelectasis or aspiration pneumonia.

Congenital Myopathies: Distinguished by normal genetic SMN1* assays and specific sarcoplasmic abnormalities on muscle biopsy.

• Infantile Botulism: Differentiated by acute onset, descending paralysis, and positive stool toxin essay.


• Amyotrophic Lateral Sclerosis (ALS): Shows mixed upper and lower motor neuron signs (spasticity, hyperreflexia), which are absent in SMA.

• Type II respiratory failure.
• Aspiration pneumonia.
• Severe scoliosis and pelvic obliquity.
• Joint contractures and osteopenia.

Historically, SMA Type 1 carried a mortality rate of >90% before age

1. With modern disease-modifying therapies, patients survive longer and achieve motor milestones like sitting and walking, especially when treated presymptomatically.

• Carrier screening for prospective parents.
• Preimplantation genetic testing (PGD).
• Newborn screening programs for early, presymptomatic intervention.

The following homeopathic remedies have been historically indicated for symptoms associated with Spinal Muscular Atrophy. Selection should be based on individualized symptom totality and constitutional assessment.

• Homeopathy by Hadhrat Mirza Tahir Ahmad (r.a.) — Primary clinical reference
• Robin Murphy — Lotus Materia Medica (3rd Edition)
• William Boericke — Pocket Manual of Homœopathic Materia Medica & Repertory
• ICD-10/ICD-11 Classification — World Health Organization
• Harrison's Principles of Internal Medicine (Reference Standard)

This clinical reference profile is compiled from authoritative medical sources for educational purposes. Always verify clinical data with current medical guidelines.

🔬 Lab Report Analyzer (Diagnostic Verification)

Upload your laboratory bloodwork PDF or paste your report text to automatically extract markers, detect units, and identify reference range variances related to Spinal Muscular Atrophy.